Gram-Positive Cocci Infections: Identification and Treatment

Introduction to Gram-Positive Cocci

The American College of Emergency Physicians and the Infectious Diseases Society of America recommend that Enterococcus species, which are frequently isolated gram-positive organisms in intra-abdominal infections (7.7-16.5% of cases), be considered in the treatment of such infections, as they are associated with worse outcomes in secondary peritonitis 1
The Infectious Diseases Society of America suggests that viridans group streptococci, which are common in polymicrobial infections, can cause serious infections, including endocarditis, and require appropriate antibiotic coverage 2

For mild community-acquired infections, the American Diabetes Association recommends that beta-hemolytic streptococci and S. aureus be considered the most likely pathogens, and narrow-spectrum therapy targeting gram-positive cocci is appropriate 3
The Infectious Diseases Society of America recommends that vancomycin be included in the initial empirical regimen when gram-positive cocci are identified in severe infections, particularly in high-risk patients, such as those with clinically suspected serious catheter-related infections, known colonization with penicillin- and cephalosporin-resistant pneumococci or methicillin-resistant S. aureus, positive blood cultures showing gram-positive bacteria before final identification, hypotension or cardiovascular impairment, or neutropenic patients with fever 2, 5

The Infectious Diseases Society of America recommends that clindamycin plus penicillin be used to treat necrotizing fasciitis caused by group A streptococci, as clindamycin suppresses toxin production and modulates cytokine response, demonstrating superior efficacy versus penicillin alone in animal studies and observational data 4
For polymicrobial intra-abdominal infections, the Society of Critical Care Medicine suggests that broad-spectrum coverage, including ampicillin-sulbactam, clindamycin, and ciprofloxacin, or alternative regimens such as piperacillin-tazobactam, carbapenems, or cefotaxime plus metronidazole, be used to treat infections involving gram-positive cocci, particularly Enterococcus species 1, 4, 6

The American College of Clinical Pharmacy recommends that standard vancomycin dosing be 15-20 mg/kg every 8-12 hours IV, with target trough concentrations of 15-20 μg/mL in severe infections 6
The Infectious Diseases Society of America suggests that alternative agents, such as linezolid, daptomycin, and ceftaroline, be used when vancomycin cannot be used 5

The Society of Critical Care Medicine recommends that rapid identification techniques, including direct bacterial identification and susceptibility testing, rapid tests to detect S. aureus and determine methicillin susceptibility, and mass spectrometry, be employed to guide early de-escalation of therapy 7
The Infectious Diseases Society of America recommends that treatment duration for most bacterial skin and soft tissue infections be 7-14 days, but therapy should be extended if infection has not improved within this timeframe, and antibiotics should continue until repeated operative procedures are no longer needed, clinical improvement is obvious, and fever has been absent for 48-72 hours 4, 5, 6